Patent ID: 7601850

Claim:
A compound represented by formula I or a pharmaceutically acceptable salt thereof: wherein; R and R′ are independently C 1 -C 5 alkyl, C 1 -C 5 fluoroalkyl, or together R and R′ form a substituted or unsubstituted, saturated or unsaturated carbocyclic ring having from 3 to 8 carbon atoms; Ring atoms Q 1 and Q 2 are independently selected from carbon or sulfur, with the proviso that one atom is sulfur and the other atom is carbon; R P is C 1 —C 5 alkyl; R T is selected from hydrogen, C 1 -C 5 alkyl, C 1 -C 5 fluoroalkyl, —O—C 1 -C 5 alkyl; (L p ) and (L T ) are divalent linking groups independently selected from the group consisting of where m is 0, 1 or 2, X 1 is oxygen or sulfur; Z p and Z T are independently selected from —(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-C(O)—(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-C(O)—(O—C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-C(O)—OH, —(C 1 -C 5 alkyl)-SO 2 —(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-S(O)—(C 1 -C 5 alkyl), —(C 1 -C 5 alkyl)-N(C(O)(C 1 -C 5 alkyl)CH 2 C(O)OH, —(C 1 -C 5 alkyl)-N(C(O)(C 1 -C 5 alkyl)CH 2 C(O)—(C 1 -C 5 alkyl), —CH(OH)—(C 1 -C 5 alkyl) —C(O)—O—(C 1 -C 5 alkyl), —C(O)—NH(OH), —C(O)—N—(C 1 -C 5 alkyl) 2 —C(O)—NH—(C 1 -C 5 alkyl)-SO 2 —(C 1 -C 5 alkyl), —C(O)—NH—(C 1 -C 5 alkyl)-S(O)—(C 1 -C 5 alkyl), —C(O)—NH—CH 2 —C(O)OH, —C(O)—NH—CH 2 —C(O)—(O—C 1 -C 5 alkyl), —C(O)—N—(C 1 -C 5 alkyl)(C(O)OH), —C(O)—N—(C 1 -C 5 alkyl)(C(O)—(O—C 1 -C 5 alkyl)), —C(O)—NH—CH((CH2)(CO 2 H))(CO 2 H), —C(O)—NH—CH((CH2)(C(O)—(C 1 -C 5 alkyl)))(C(O)—(O—C 1 C 5 alkyl)), —C(O)—NH—CH((CH 2 )(C(O)—(—O—C 1 -C 5 alkyl)))(C(O)—(O—C 1 C 5 alkyl)), —C(O)—NH—CH((CH 2 OH)(CO 2 H)), —C(O)—NH—CH((CH 2 OH)(C(O)(O—C 1 -C 5 alkyl)), —C(O)—NH—C((C 1 -C 5 alkyl)(C 1 -C 5 alkyl))(CO 2 H), —C(O)—NH—C((C 1 -C 5 alkyl)(C 1 -C 5 alkyl))(C(O)—(O—C 1 -C 5 alkyl)), —C(O)—NH—5-tetrazolyl, —C(O)—N-pyrrolidin-2-(CO 2 H), —C(O)—N-pyrrolidin-2-(C(O)—(O—C 1 -C 5 alkyl)), —C(O)—N—(C 1 -C 5 alkyl))CH 2 (CO 2 H), —O—(C 1 -C 5 alkyl)-C(O)—OH, —O—(C 1 -C 5 alkyl)-C(O)—NH—5-tetrazolyl, —O—(C 1 -C 5 alkyl)-C(O)—(C 1 -C 5 alkyl), —O—(C 1 -C 5 alkyl)-C(O)—(O—C 1 -C 5 alkyl), —O—(C 1 -C 5 alkyl)-S(O)—(C 1 -C 5 alkyl), —O—SO 2 —(C 1 -C 5 alkyl), —SO 2 —(C 1 -C 5 alkyl), —SO 2 —NH 2 , —SO 2 —NH—(C 1 -C 5 alkyl)-C(O)OH, —SO 2 —NH—(C 1 -C 5 alkyl)-C(O)(O—C 1 -C 5 alkyl), —SO 2 —NHC(O)—(C 3 -C 6 cycloalkyl), —SO 2 —NH—C(O)—(C 1 -C 5 alkyl), —SO 2 —N—(C 1 -C 5 alkyl) 2 , —SO 2 —N═CHN(C 1 -C 5 alkyl) 2 , —N(OH)(CH 3 ), —I, —Br —Cl —F, provided that the combined groups of formula I represented by may both be lipophilic, or either one may be lipophilic and the other one polar; but both combined groups may not be polar.